Bosch Developing COVID-19-(SARS-CoV-2) Rapid Testing Kit for the Vivalytic Platform

Date : 26/03/2020 @ 16:09
Source : PR Newswire (US)

Bosch Developing COVID-19-(SARS-CoV-2) Rapid Testing Kit for the Vivalytic Platform

Test delivers reliable results at the point of care in less than 2.5 hours

 - One of the world's first multiplex molecular diagnostic tests that can identify COVID-19 and distinguish it from nine other respiratory infections with similar symptoms, like influenza

 - The test meets the requirements of the World Health Organization (WHO) and was developed together with Randox Laboratories Ltd.

WAIBLINGEN, Germany, March 26, 2020 /PRNewswire/ -- Bosch Healthcare Solutions is currently working on the development of a COVID-19 rapid testing kit for the Vivalytic platform and will launch this in April 2020. The Vivalytic VRI test (Viral Respiratory Tract Infections) checks the patient's sample for the SARS CoV-2 virus, which can lead to COVID-19, as well as nine other possible viral respiratory diseases. To prevent the continued rapid spread of COVID-19, it is necessary to identify infectious patients with and without symptoms. With the Vivalytic VRI test, physicians can quickly and efficiently distinguish between different infections with very similar symptoms, like influenza, and immediately begin the appropriate treatment. The test delivers a reliable result based on WHO guidelines in less than 2.5 hours at the point of care, i.e. in close proximity to where the patient's sample was collected. This means a time-consuming logistics chain, in which the samples have to be transported, is no longer necessary.

The COVID-19-(SARS-CoV-2-) rapid testing kit for the Vivalytic platform developed by Bosch delivers reliable results at the point of care in less than 2.5 hours

"Together with our partner Randox, we have adapted the manual COVID-19 test, which has existed just a few weeks, to the new, fully automated Vivalytic platform from Bosch," said Marc Meier, Managing Director of Bosch Healthcare Solutions GmbH. "Thanks to the extensive expertise of both companies, we have succeeded in developing an innovative test in a very short time, which can contribute to curbing the global spread of the coronavirus."

The Vivalytic platform is so easy to use that it can be handled in any clinic or medical practice without the need for laboratory personnel: The sample is taken from the patient's nose or throat using a swab and placed in the cartridge without any complex preparation. The Vivalytic analyser then fully automatically processes the cartridge, which already contains all the reagents required for the test. Since the system in each cartridge is isolated, the risk of infection during handling is minimized.

Vivalytic is a universal platform for molecular diagnostics that can be used to perform various fully automatic laboratory tests in a short time. The open design of the platform makes it compatible with manual tests from various suppliers. The range of available tests is expected to grow steadily, enabling physicians to initiate successful therapies based on rapid diagnosis.

Photo: https://mma.prnewswire.com/media/1135729/Vivalytic_VRI_test.jpg
Photo: https://mma.prnewswire.com/media/1135730/Bosch_Vivalytic_VRI.jpg

Press contact:
Thomas Berroth
Marketing & Communication
Thomas.berroth2@de.bosch.com
+4971181145599

www.bosch-vivalytic.com
 

Running the test is easy: The sample is taken from patient’s nose or throat using a swab and placed without further preparation in the cartridge - which is then fully automatically processed in the Vivalytic analyser.

Copyright 2020 PR Newswire

$
ADVFN Advertorial
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200328 09:59:30